In a report released today, Yun Zhong from Wedbush maintained a Buy rating on MannKind, with a price target of $11.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yun Zhong’s rating is based on several key factors that highlight the potential for MannKind’s growth. The company’s partner, United Therapeutics, has demonstrated strong performance with its product Tyvaso DPI, showing significant revenue growth and a competitive edge in the market. This growth is attributed to an increase in patient numbers and strategic pricing, which suggests a robust demand for the product.
Furthermore, MannKind’s own pipeline, particularly the MNKD-201 program for idiopathic pulmonary fibrosis (IPF), presents additional opportunities for expansion. The upcoming regulatory discussions with the FDA and potential positive outcomes from the TETON studies could further enhance MannKind’s market position. These elements collectively support the Buy rating, indicating confidence in the company’s future prospects.
Zhong covers the Healthcare sector, focusing on stocks such as MannKind, Rocket Pharmaceuticals, and Ascendis Pharma. According to TipRanks, Zhong has an average return of -16.7% and a 36.79% success rate on recommended stocks.
In another report released on July 23, RBC Capital also maintained a Buy rating on the stock with a $8.00 price target.